EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Progressive narcolepsy: how to deal with intermediate hypocretin-1 values?

François Ricordeau, Agathe Bridoux, Véronique Raverot, Laure Peter-Derex

Journal of Clinical Sleep Medicine · 2023

DOI: 10.5664/jcsm.10576 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Clinical Sleep Medicine, 2023. Verfasst von François Ricordeau und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Sleep Medicine and Respiratory Diseases, Croix-Rousse Hospital, Lyon Academic Hospital, Lyon 1 University, Lyon, France. Hauptthemen laut MEDLINE: Neuropeptides, Narcolepsy, Disorders of Excessive Somnolence, Cataplexy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

According to the International Classification of Sleep Disorders, third edition guidelines, the diagnosis of narcolepsy type 1 is based on the association of excessive daytime sleepiness plus either cataplexy and electrophysiological criteria, or a cerebrospinal fluid hypocretin-1 concentration below 110 pg/mL. This threshold remains debated, and recent works have proposed alternative values in the intermediate (110 to 200 pg/mL) zone. We report the case of a patient who presented with typical clinical symptoms of narcolepsy type 1 developing over six years but in whom initial polysomnography and multiple sleep latency test were negative and cerebrospinal fluid hypocretin-1 was intermediate (132 pg/mL). Cerebrospinal fluid hypocretin-1 reassessment four years later found a dramatic decrease, < 50 pg/mL, and the multiple sleep latency test proved to be abnormal, eventually allowing to confirm the diagnosis. This case highlights the importance of reassessing patients with intermediate hypocretin-1 values and contributes to the debate on the determination of alternative cerebrospinal fluid hypocretin1 thresholds for narcolepsy type 1 diagnosis. CITATION: Ricordeau F, Bridoux A, Raverot V, Peter-Derex L. Progressive narcolepsy: how to deal with intermediate hypocretin-1 values? J Clin Sleep Med. 2023;19(7):1375-1378.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuropeptidesNarcolepsyDisorders of Excessive SomnolenceCataplexyHumansOrexinsIntracellular Signaling Peptides and Proteins

Stichwörter der Autor:innen

cataplexymultiple sleep latency testnarcolepsyorexin

Substanzen

OrexinsNeuropeptidesIntracellular Signaling Peptides and Proteins

Autor:innen und Institutionen

  • Center for Sleep Medicine and Respiratory Diseases, Croix-Rousse Hospital, Lyon Academic Hospital, Lyon 1 University, Lyon, France.
  • Service de Biochimie et biologie moléculaire, Hospices Civils de Lyon, LBMMS, F-69677 Hormonologie, Bron cedex, France.
  • Neuroscience Research Center (CRNL), Inserm UMRS 1028, Université de Lyon, Waking team, Bron, France.
  • Lyon Neuroscience Research Centre, CNRS UMR 5292-INSERM U1028, Bron, France.

Zitieren

APA

Ricordeau, F., Bridoux, A., Raverot, V., & Peter-Derex, L. (2023). Progressive narcolepsy: how to deal with intermediate hypocretin-1 values?. Journal of Clinical Sleep Medicine. https://doi.org/10.5664/jcsm.10576

Vancouver

Ricordeau F, Bridoux A, Raverot V, Peter-Derex L. Progressive narcolepsy: how to deal with intermediate hypocretin-1 values?. Journal of Clinical Sleep Medicine. 2023. doi:10.5664/jcsm.10576

BibTeX
@article{Ricordeau2023,
  author = {Ricordeau, François and Bridoux, Agathe and Raverot, Véronique and Peter-Derex, Laure},
  title = {Progressive narcolepsy: how to deal with intermediate hypocretin-1 values?},
  journal = {Journal of Clinical Sleep Medicine},
  year = {2023},
  doi = {10.5664/jcsm.10576}
}
Kostenlos starten →